MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Clinical Care Options Oncology - Leukemia' source. Wed, 08 Feb 2012 17:41:59 +0100 http://www.medworm.com/index.php?rid=5668079&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCLL.aspx Learning Module - In this CME-certified slideset, John C. Byrd, MD, and Kanti Rai, MD, explore the most compelling data in chronic lymphocytic leukemia presented in San Diego. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5668079 Tue, 07 Feb 2012 15:36:47 +0100 5668079 http://www.medworm.com/index.php?rid=5572777&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCML%2FCapsules%2F3761.aspx Capsule Summary - Novel, first-in-class cetaxine demonstrates efficacy in heavily pretreated patients with chronic- or accelerated-phase chronic myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572777 Mon, 19 Dec 2011 12:28:43 +0100 5572777 http://www.medworm.com/index.php?rid=5572778&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F3901.aspx Capsule Summary - Among patients with refractory CLL, the bendamustine/fludarabine/rituximab regimen elicited an ORR of 88%, including CR in 29% of patients, and was generally well tolerated. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572778 Mon, 19 Dec 2011 12:04:29 +0100 5572778 http://www.medworm.com/index.php?rid=5572779&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCML%2FCapsules%2F453.aspx Capsule Summary - Sequential nilotinib and imatinib shown active in untreated early chronic-phase CML, although efficacy relative to standard treatment strategies is unclear. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572779 Mon, 19 Dec 2011 09:20:17 +0100 5572779 http://www.medworm.com/index.php?rid=5572780&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCML%2FCapsules%2F1700.aspx Capsule Summary - Results showed a 100% rate of complete cytogenetic response, a 90% rate of major molecular response, and no transformations to AP/BP CML over 3 years. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572780 Fri, 16 Dec 2011 18:32:56 +0100 5572780 http://www.medworm.com/index.php?rid=5572781&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FMDS%2FCapsules%2F794.aspx Capsule Summary - Novel HDAC inhibitor, panobinostat, reduces spleen size in patients with myelofibrosis in an exploratory study, but with a cost of hematologic toxicities. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572781 Fri, 16 Dec 2011 16:22:40 +0100 5572781 http://www.medworm.com/index.php?rid=5572782&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F2865.aspx Capsule Summary - In this phase I trial involving 13 patients, the most frequent adverse events with obatoclax plus fludarabine and rituximab were grade 1-2 euphoria, dizziness, and ataxia and grade 3 or higher neutropenia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572782 Fri, 16 Dec 2011 15:57:05 +0100 5572782 http://www.medworm.com/index.php?rid=5572783&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCML%2FCapsules%2F455.aspx Capsule Summary - Two-year follow-up from the randomized BELA study finds bosutinib improves molecular response rates vs imatinib, but with greater risk of toxicity-driven discontinuations. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572783 Fri, 16 Dec 2011 13:06:15 +0100 5572783 http://www.medworm.com/index.php?rid=5572784&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FMDS%2FCapsules%2F2576.aspx Capsule Summary - Quizartinib achieved clinically meaningful responses in patients with refractory FLT3-ITD–positive AML, including CRs in 40% and transition to HSCT in 21%. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572784 Fri, 16 Dec 2011 11:51:13 +0100 5572784 http://www.medworm.com/index.php?rid=5572785&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCML%2FCapsules%2F603.aspx Capsule Summary - Sokal score and duration of imatinib therapy were identified as independent predictors of relapse among patients with CML who discontinued imatinib therapy after sustaining complete molecular remission for 2 or more years. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572785 Fri, 16 Dec 2011 11:42:39 +0100 5572785 http://www.medworm.com/index.php?rid=5572786&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F289.aspx Capsule Summary - Benefits derived by younger CLL patients following use of initial fludarabine therapy are not matched in older patients. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572786 Fri, 16 Dec 2011 11:33:41 +0100 5572786 http://www.medworm.com/index.php?rid=5572787&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F3912.aspx Capsule Summary - In this challenging-to-treat group of patients, ofatumumab produced up to an 85% response rate with low rates of adverse events. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572787 Fri, 16 Dec 2011 11:22:32 +0100 5572787 http://www.medworm.com/index.php?rid=5572788&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCML%2FCapsules%2F451.aspx Capsule Summary - Early intervention for chronic-phase CML patients who respond poorly to first-line imatinib may improve long-term response. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572788 Fri, 16 Dec 2011 11:11:27 +0100 5572788 http://www.medworm.com/index.php?rid=5572789&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FMDS%2FCapsules%2F80.aspx Capsule Summary - Adding ATRA to chemotherapy for NPM1-mutated AML significantly increased response rates and improved event free survival and may be a new standard of care. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572789 Thu, 15 Dec 2011 18:59:23 +0100 5572789 http://www.medworm.com/index.php?rid=5572790&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FMDS%2FCapsules%2F875.aspx Capsule Summary - In a phase I study of patients with relapsed/refractory ALL, inotuzumab produced a 57% ORR and was generally well tolerated. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572790 Thu, 15 Dec 2011 16:01:44 +0100 5572790 http://www.medworm.com/index.php?rid=5572791&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F294.aspx Capsule Summary - Sixty percent of untreated, elderly CLL patients achieve at least a PR following rituximab/chlorambucil induction therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572791 Thu, 15 Dec 2011 15:06:28 +0100 5572791 http://www.medworm.com/index.php?rid=5572792&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FMDS%2FCapsules%2F6.aspx Capsule Summary - Event-free survival and OS benefits restricted to patients with favorable or intermediate cytogenetics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572792 Thu, 15 Dec 2011 13:04:00 +0100 5572792 http://www.medworm.com/index.php?rid=5572793&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FMDS%2FCapsules%2F763.aspx Capsule Summary - The most common adverse events observed with vorinostat, idarubicin, and high-dose cytarabine in this phase II study were gastrointestinal in nature. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572793 Thu, 15 Dec 2011 12:48:00 +0100 5572793 http://www.medworm.com/index.php?rid=5572794&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F977.aspx Capsule Summary - In this subset analysis of the German CLL Study Group CLL8 trial, median PFS and median OS were both significantly longer in patients identified as having low- vs high-risk disease. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572794 Thu, 15 Dec 2011 12:14:47 +0100 5572794 http://www.medworm.com/index.php?rid=5572795&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F291.aspx Capsule Summary - In this nonrandomized phase II trial, ORR and CR rates were higher in patients younger than 65 years of age compared with patients 65 years of age or older. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572795 Thu, 15 Dec 2011 10:43:42 +0100 5572795 http://www.medworm.com/index.php?rid=5572796&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2011%2FTracks%2FCLL%2FCapsules%2F2859.aspx Capsule Summary - In this interim analysis at a median of 3 lenalidomide cycles, only 2 cases of serious tumor lysis syndrome have been reported, and more than one half of enrolled patients remain on treatment. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5572796 Wed, 14 Dec 2011 16:15:45 +0100 5572796 http://www.medworm.com/index.php?rid=5506065&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202011%2FTracks%2FCLL%2FCapsules%2F980.aspx Capsule Summary - In this single-arm phase II trial, patients with fludarabine-refractory disease experienced lower response rates to lenalidomide plus rituximab compared with patients whose disease was not refractory to fludarabine; however, this subgroup analysis was limited by low patient numbers. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5506065 Wed, 14 Dec 2011 15:47:29 +0100 5506065 http://www.medworm.com/index.php?rid=5506066&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202011%2FTracks%2FCML%2FCapsules%2F452.aspx Capsule Summary - Frontline nilotinib 300 mg or 400 mg BID produced higher response rates and decreased risk of progression to AP/BC. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5506066 Wed, 14 Dec 2011 13:28:59 +0100 5506066 http://www.medworm.com/index.php?rid=5021731&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FCML%2520Expert%2520Roundtable%2FModule%2FCML%2520Expert%2520Roundtable.aspx Learning Module - In this interactive CME-certified activity, compare your management of a patient with chronic myeloid leukemia as he progresses from newly diagnosed to advanced disease with evidence-based treatment strategies and perspectives from a roundtable among Jerald Radich, MD; Michael J. Mauro, MD; and B. Douglas Smith, MD. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=5021731 Tue, 21 Jun 2011 10:06:04 +0100 5021731 http://www.medworm.com/index.php?rid=4914627&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202011%2FTracks%2FHematologic%2520Malignancies%2FCapsules%2F6504.aspx Capsule Summary - In a randomized phase III trial, decitabine prolonged OS in older patients with newly diagnosed AML. The safety profile of decitabine was comparable to that of low-dose cytarabine. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4914627 Wed, 08 Jun 2011 17:04:46 +0100 4914627 http://www.medworm.com/index.php?rid=4914628&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202011%2FTracks%2FHematologic%2520Malignancies%2FCapsules%2F6503.aspx Capsule Summary - In a phase III trial, clofarabine combined with cytarabine improved EFS and elicited higher response rates. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4914628 Wed, 08 Jun 2011 13:31:56 +0100 4914628 http://www.medworm.com/index.php?rid=4412555&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCML.aspx Learning Module - In this Expert Analysis, Jerald Radich, MD, and Moshe Talpaz, MD, review and discuss the most clinically relevant new findings on chronic myeloid leukemia reported at the 2010 American Society of Hematology annual meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4412555 Thu, 27 Jan 2011 15:28:41 +0100 4412555 http://www.medworm.com/index.php?rid=4407368&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCLL%2FCLL.aspx Learning Module - In this Expert Analysis, John C. Byrd, MD; Susan M. O’Brien, MD; and Kanti Rai, MD, review and discuss the most clinically relevant new findings on chronic lymphocytic leukemia reported at the 2010 American Society of Hematology annual meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4407368 Thu, 27 Jan 2011 08:54:35 +0100 4407368 http://www.medworm.com/index.php?rid=4346031&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FCCO%2520Slidesets%2FChronic%2520Myeloid%2520Leukemia.aspx CCO Slideset - Download slides on the most recent findings in CML presented at the Hematology 2011 annual conference. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4346031 Thu, 13 Jan 2011 00:00:00 +0100 4346031 http://www.medworm.com/index.php?rid=4251619&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCLL%2FCapsules%2F921.aspx Capsule Summary - Ofatumumab monotherapy associated with high ORR in patients with refractory, high-risk CLL, independent of previous therapy, age, stage, and number of previous regimens. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4251619 Sat, 11 Dec 2010 17:07:39 +0100 4251619 http://www.medworm.com/index.php?rid=4251620&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F3436.aspx Capsule Summary - According to a Bayesian meta-analysis, there is no significant difference in CCyR and MMR rate between dasatinib and nilotinib, but both were superior to imatinib as first-line therapy in CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4251620 Sat, 11 Dec 2010 16:53:43 +0100 4251620 http://www.medworm.com/index.php?rid=4251621&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F208.aspx Capsule Summary - Bosutinib associated with higher major molecular response rate at 12 months and lower rates of transformation to accelerated phase or blast phase vs imatinib in untreated patients with CML-CP. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4251621 Sat, 11 Dec 2010 15:04:02 +0100 4251621 http://www.medworm.com/index.php?rid=4250065&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2FLBA6.aspx Capsule Summary - Dasatinib treatment was associated with a greater median log reduction in BCR-ABL transcript levels at 12 months relative to imatinib; however, rates of CHR, CCyR, OS, PFS were similar in both treatment arms. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4250065 Fri, 10 Dec 2010 19:19:48 +0100 4250065 http://www.medworm.com/index.php?rid=4250066&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F207.aspx Capsule Summary - After 2 years of follow-up, rates of complete cytogenetic response and major molecular response were higher and achieved more rapidly with nilotinib vs imatinib. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4250066 Fri, 10 Dec 2010 18:42:44 +0100 4250066 http://www.medworm.com/index.php?rid=4250067&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCLL%2FCapsules%2F924.aspx Capsule Summary - In patients receiving first-line treatment for CLL, incidence of therapy-related myeloid neoplasm increased numerically, but not statistically significantly greater with use of fludarabine/cyclophosphamide vs fludarabine alone. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4250067 Fri, 10 Dec 2010 17:19:56 +0100 4250067 http://www.medworm.com/index.php?rid=4246767&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F891.aspx Capsule Summary - In this retrospective analysis of patients with CML after imatinib failure, the presence of multiple low-level mutations detected using a mass spectrometry–based method was associated with a lower rate of complete cytogenetic response to second-line nilotinib or dasatinib treatment of CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4246767 Thu, 09 Dec 2010 19:16:21 +0100 4246767 http://www.medworm.com/index.php?rid=4246768&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F206.aspx Capsule Summary - At a median follow-up of 18 months, rates of complete cytogenetic response and major molecular response were higher and achieved more rapidly with dasatinib. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4246768 Thu, 09 Dec 2010 17:32:17 +0100 4246768 http://www.medworm.com/index.php?rid=4246769&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FMDS%2FCapsules%2F601.aspx Capsule Summary - Combined entinostat plus azacitidine resulted in increased toxicity vs azacitidine alone. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4246769 Thu, 09 Dec 2010 15:01:32 +0100 4246769 http://www.medworm.com/index.php?rid=4246770&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FMDS%2FCapsules%2F655.aspx Capsule Summary - CPX-351 was associated with low early mortality in treatment-naive elderly patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4246770 Thu, 09 Dec 2010 11:45:16 +0100 4246770 http://www.medworm.com/index.php?rid=4239033&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FMDS%2FCapsules%2F13.aspx Capsule Summary - 5-year EFS found to be significantly lower for standard-risk APL patients not receiving Ara-C vs those receiving Ara-C. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4239033 Tue, 07 Dec 2010 16:30:03 +0100 4239033 http://www.medworm.com/index.php?rid=4234536&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FMDS%2FCapsules%2F99.aspx Capsule Summary - DNMT3A gene mutation analysis may help predict prognosis in intermediate-risk cases of AML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4234536 Mon, 06 Dec 2010 19:36:08 +0100 4234536 http://www.medworm.com/index.php?rid=4234537&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FLymphomas%2FCapsules%2F11.aspx Capsule Summary - Pharmacologic AKT inhibition restored sensitivity to dexamethasone-induced apoptosis in T-cell ALL cell lines and primary samples. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4234537 Mon, 06 Dec 2010 18:42:28 +0100 4234537 http://www.medworm.com/index.php?rid=4234538&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F2297.aspx Capsule Summary - Combined results from 3 dasatinib clinical trials indicate that 2-year PFS rates were similar across all mutation groups among patients with complete cytogenetic response at 1 year whereas 2-year PFS rates were reduced in the presence of ≥ 2 (vs 0-1) baseline mutations among patients with partial cytogenetic response or less at 1 year. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4234538 Mon, 06 Dec 2010 10:19:36 +0100 4234538 http://www.medworm.com/index.php?rid=4231193&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCLL%2FCapsules%2F1382.aspx Capsule Summary - The benefit of rituximab maintenance therapy was greatest for patients who achieved CR with MRD after induction treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4231193 Sun, 05 Dec 2010 16:56:09 +0100 4231193 http://www.medworm.com/index.php?rid=4231194&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCML%2FCapsules%2F1204.aspx Capsule Summary - Lymphocyte mobilization following dasatinib treatment not observed following administration of other tyrosine kinase inhibitors, including imatinib, nilotinib, and bosutinib. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4231194 Sun, 05 Dec 2010 15:38:51 +0100 4231194 http://www.medworm.com/index.php?rid=4231195&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202010%2FTracks%2FCLL%2FCapsules%2F1379.aspx Capsule Summary - In this nonrandomized, prospective trial, lenalidomide consolidation following pentostatin, cyclophosphamide, and rituximab induction appeared to prolong the time to retreatment compared with a previous trial evaluating pentostatin, cyclophosphamide, and rituximab without lenalidomide. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4231195 Sun, 05 Dec 2010 15:37:21 +0100 4231195 http://www.medworm.com/index.php?rid=4221494&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FClin+Onc+June+2010%2FTracks%2FHematologic+Malignancies%2FHematologic_Malignancies.aspx Learning Module - CCO’s expert faculty members review the clinical implications of new hematologic cancer data presented at the 2010 ASCO annual meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221494 Tue, 31 Aug 2010 09:49:10 +0100 4221494 http://www.medworm.com/index.php?rid=4221496&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FClin+Onc+June+2010%2FTracks%2FHematologic+Malignancies%2FCapsules%2F6501.aspx Capsule Summary - Nilotinib was generally well tolerated at 300 mg BID and 400 mg BID doses and demonstrated similar grade 3/4 adverse event rates to imatinib 400 mg QD. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221496 Fri, 11 Jun 2010 19:23:54 +0100 4221496 http://www.medworm.com/index.php?rid=3654078&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202010%2FTracks%2FHematologic%2520Malignancies%2FCapsules%2F6501.aspx Capsule Summary - Nilotinib was generally well tolerated at 300 mg BID and 400 mg BID doses and demonstrated similar grade 3/4 adverse event rates to imatinib 400 mg QD. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3654078 Fri, 11 Jun 2010 19:23:54 +0100 3654078 http://www.medworm.com/index.php?rid=4221497&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FClin+Onc+June+2010%2FTracks%2FHematologic+Malignancies%2FCapsules%2F6517.aspx Capsule Summary - The incidence of grade 3/4 events was similar across treatment arms; longer follow-up is needed to determine the impact of imatinib 800-mg dose on survival. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221497 Fri, 11 Jun 2010 19:02:53 +0100 4221497 http://www.medworm.com/index.php?rid=4221498&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FClin+Onc+June+2010%2FTracks%2FHematologic+Malignancies%2FCapsules%2F6502.aspx Capsule Summary - In this phase I/II trial, bosutinib treatment was associated with a 91% rate of complete hematologic response, a 50% rate of complete cytogenetic response, and a 52% rate of major molecular response; 19% of patients discontinued treatment because of toxicity. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221498 Fri, 11 Jun 2010 12:41:07 +0100 4221498 http://www.medworm.com/index.php?rid=4221499&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FClin+Onc+June+2010%2FTracks%2FHematologic+Malignancies%2FCapsules%2F6512.aspx Capsule Summary - Cytogenetic responses at 6 and 12 months were predictive of 4-year PFS with dasatinib 100 mg once daily. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221499 Thu, 10 Jun 2010 00:00:00 +0100 4221499 http://www.medworm.com/index.php?rid=4221500&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2009%2FTracks%2FCML%2FCML.aspx Learning Module - Join Brian Druker, MD; Elias Jabbour, MD; Neil P. Shah, MD, PhD; and Moshe Talpaz, MD, as they review the clinical implications of research on chronic myelogenous leukemia presented at the 2009 Hematology meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221500 Tue, 02 Mar 2010 12:00:00 +0100 4221500 http://www.medworm.com/index.php?rid=4221501&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2009%2FTracks%2FALL+and+AML%2FALL_and_AML.aspx Learning Module - Dan Douer, MD; Hagop M. Kantarjian, MD; Farhad Ravandi, MD; and Martin S. Tallman, MD, discuss the clinical implications of study data presented at the 2009 Hematology meeting on the treatment of AML and ALL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221501 Fri, 26 Feb 2010 12:00:00 +0100 4221501 http://www.medworm.com/index.php?rid=4221502&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FAppelbaum.aspx CCO Slideset - Download a slideset in which Frederick Appelbaum, MD, explores the improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221502 Wed, 17 Feb 2010 10:56:47 +0100 4221502 http://www.medworm.com/index.php?rid=4221503&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FAllogeneic_HCT_in_AML.aspx CCO Virtual Presentation - Frederick R. Appelbaum, MD, explores the changes that have improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221503 Wed, 17 Feb 2010 10:56:09 +0100 4221503 http://www.medworm.com/index.php?rid=4221506&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FConfer.aspx CCO Slideset - Download a slideset in which Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221506 Fri, 12 Feb 2010 12:00:00 +0100 4221506 http://www.medworm.com/index.php?rid=4221505&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FDevine.aspx CCO Slideset - Download a slideset in which Steven Devine, MD, provides up-to-date information on risk stratification in patients with AML, and discusses how this affects treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221505 Fri, 12 Feb 2010 12:00:00 +0100 4221505 http://www.medworm.com/index.php?rid=4221504&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FAML_MDS_Transplantation_Trials.aspx CCO Virtual Presentation - Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS, including studies available through the Blood and Marrow Transplant Clinical Trials Network. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221504 Fri, 12 Feb 2010 12:00:00 +0100 4221504 http://www.medworm.com/index.php?rid=3277528&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FConfer.aspx CCO Slideset - Download a slideset in which Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277528 Fri, 12 Feb 2010 12:00:00 +0100 3277528 http://www.medworm.com/index.php?rid=3277527&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FDevine.aspx CCO Slideset - Download a slideset in which Steven Devine, MD, provides up-to-date information on risk stratification in patients with AML, and discusses how this affects treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277527 Fri, 12 Feb 2010 12:00:00 +0100 3277527 http://www.medworm.com/index.php?rid=3277526&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FAML_MDS_Transplantation_Trials.aspx CCO Virtual Presentation - Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS, including studies available through the Blood and Marrow Transplant Clinical Trials Network. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277526 Fri, 12 Feb 2010 12:00:00 +0100 3277526 http://www.medworm.com/index.php?rid=4221507&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FOptions_for_High-Risk_AML_and_MDS.aspx CCO Virtual Presentation - Daniel Weisdorf, MD, provides an overview of the considerations for allogeneic transplantation in patients with high-risk AML or those with MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221507 Thu, 11 Feb 2010 12:00:00 +0100 4221507 http://www.medworm.com/index.php?rid=3277529&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FOptions_for_High-Risk_AML_and_MDS.aspx CCO Virtual Presentation - Daniel Weisdorf, MD, provides an overview of the considerations for allogeneic transplantation in patients with high-risk AML or those with MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277529 Thu, 11 Feb 2010 12:00:00 +0100 3277529 http://www.medworm.com/index.php?rid=3277530&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FAML%2520and%2520MDS%2520Therapies%2FVirtual%2520Presentations%2FAllogeneic_HCT_in_AML.aspx CCO Virtual Presentation - Frederick R. Appelbaum, MD, explores the changes that have improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3277530 Wed, 10 Feb 2010 11:42:40 +0100 3277530 http://www.medworm.com/index.php?rid=3260648&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FAppelbaum.aspx CCO Slideset - Download a slideset in which Frederick Appelbaum, MD, explores the changes improved outcomes of allogeneic transplantation in patients with acute myeloid leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3260648 Wed, 10 Feb 2010 11:41:13 +0100 3260648 http://www.medworm.com/index.php?rid=4221508&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FWeisdorf.aspx CCO Slideset - Download a slideset in which Daniel Weisdorf, MD, provides an overview of considerations for allogeneic transplantation in patients with high-risk AML or those with MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221508 Wed, 10 Feb 2010 00:00:00 +0100 4221508 http://www.medworm.com/index.php?rid=3256539&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FAML_MDS_Transplantation_Trials.aspx CCO Virtual Presentation - Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials, including studies available through the Blood and Marrow Transplant Clinical Trials Network, in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3256539 Tue, 09 Feb 2010 12:00:00 +0100 3256539 http://www.medworm.com/index.php?rid=3260650&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FConfer.aspx CCO Slideset - Download a slideset in which Dennis L. Confer, MD, highlights the essential role of multicenter clinical trials in expanding transplantation access and identifying optimal treatment approaches for patients with AML and MDS. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3260650 Tue, 09 Feb 2010 00:00:00 +0100 3260650 http://www.medworm.com/index.php?rid=4221509&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment+Updates%2FAML+and+MDS+Therapies%2FVirtual+Presentations%2FAML_Risk_Stratification.aspx CCO Virtual Presentation - Steven M. Devine, MD, provides up-to-date information on risk stratification in patients with AML and discusses how data on karyotyping, molecular markers, and age affect treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221509 Thu, 04 Feb 2010 16:03:32 +0100 4221509 http://www.medworm.com/index.php?rid=3241353&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FNMDP%2520Satellite%25202009%2FVirtual%2520Presentations%2FDevine.aspx CCO Slideset - Download a slideset in which Steven Devine, MD, provides up-to-date information on risk stratification in patients with AML, and discusses how this affects treatment choices. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3241353 Thu, 04 Feb 2010 00:00:00 +0100 3241353 http://www.medworm.com/index.php?rid=4221510&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2009%2FCCO+Slidesets%2FAcute_Leukemias.aspx CCO Slideset - Hagop Kantarjian MD, provides a slideset summary of the most notable studies in ALL, AML, and MDS presented at the 2009 Hematology Annual Meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221510 Mon, 11 Jan 2010 00:00:00 +0100 4221510 http://www.medworm.com/index.php?rid=4221511&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2009%2FTracks%2FALL+and+AML%2FCapsules%2F788.aspx Capsule Summary - Results of a phase II trial of FLT3 inhibitor lestaurtinib in combination with chemotherapy in AML patients in first relapse show no additional clinical activity and identified unfavorable pharmacokinetics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221511 Fri, 11 Dec 2009 16:13:55 +0100 4221511 http://www.medworm.com/index.php?rid=4221512&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2009%2FTracks%2FALL+and+AML%2FCapsules%2F790.aspx Capsule Summary - Although there was no benefit to adding gemtuzumab ozogamicin to induction therapy, consolidation with this agent was associated with a potential relapse-free survival benefit among AML patients with favorable cytogenetics. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221512 Fri, 11 Dec 2009 14:19:59 +0100 4221512 http://www.medworm.com/index.php?rid=4221513&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference+Coverage%2FHematology+2009%2FTracks%2FALL+and+AML%2FCapsules%2F842.aspx Capsule Summary - CRs to high-dose lenalidomide induction persisted for > 6 months in 40% of responding patients in this single-arm phase II trial. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=4221513 Fri, 11 Dec 2009 08:44:58 +0100 4221513 http://www.medworm.com/index.php?rid=3077151&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F859.aspx Capsule Summary - One-year results from the prospective, multicenter STIM study show the likelihood of sustained CMR 12 months following imatinib discontinuation was higher among male vs female patients and among patients with low vs intermediate or high Sokal scores. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077151 Thu, 10 Dec 2009 17:49:13 +0100 3077151 http://www.medworm.com/index.php?rid=3077152&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F339.aspx Capsule Summary - MMR-specific results of the randomized German CML Study IV showed a higher rate of MMR and more rapid response, but not improved survival, for imatinib 800 mg vs 400 mg with or without interferon in patients with newly diagnosed Ph-positive CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077152 Thu, 10 Dec 2009 13:28:14 +0100 3077152 http://www.medworm.com/index.php?rid=3077153&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F341.aspx Capsule Summary - Results of a phase II single-arm study of nilotinib as first-line treatment of patients with chronic-phase Ph-positive CML show rapid efficacy with acceptable toxicities. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077153 Thu, 10 Dec 2009 13:09:29 +0100 3077153 http://www.medworm.com/index.php?rid=3077155&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F944.aspx Capsule Summary - There was a trend toward improved outcomes with the 10-mg dose, with similar safety and no evidence of increased AML progression vs an untreated population, in this phase III randomized trial. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077155 Thu, 10 Dec 2009 12:00:00 +0100 3077155 http://www.medworm.com/index.php?rid=3077154&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F644.aspx Capsule Summary - In 2 single-arm multicenter phase II/III trials of omacetaxine, myelosuppression was the most frequent grade 3/4 toxicity and ≥ grade 3 nonhematologic adverse events were infrequent. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3077154 Thu, 10 Dec 2009 12:00:00 +0100 3077154 http://www.medworm.com/index.php?rid=3073110&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCLL%2FCapsules%2F537.aspx Capsule Summary - Significantly higher ORR and CR rate seen with fludarabine plus alemtuzumab compared with fludarabine alone. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073110 Wed, 09 Dec 2009 20:06:11 +0100 3073110 http://www.medworm.com/index.php?rid=3073111&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F338.aspx Capsule Summary - Randomized phase II study results show high response rates with both once-daily and twice-daily dasatinib dosing for first-line treatment of CML, although dose reductions were more frequent with twice-daily dosing. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073111 Wed, 09 Dec 2009 19:38:32 +0100 3073111 http://www.medworm.com/index.php?rid=3073112&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F119.aspx Capsule Summary - In this phase II study, response rates to decitabine therapy were higher with daily dosing vs weekly low-intensity dosing. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073112 Wed, 09 Dec 2009 15:15:22 +0100 3073112 http://www.medworm.com/index.php?rid=3073113&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2F337.aspx Capsule Summary - Lower rates of MMR and CCyR were observed in patients who had ≥ 2 dose interruptions. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073113 Wed, 09 Dec 2009 13:26:49 +0100 3073113 http://www.medworm.com/index.php?rid=3073114&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F636.aspx Capsule Summary - In the first in-human study, AC220 responses higher in AML patients harboring FLT3 internal tandem duplications. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073114 Wed, 09 Dec 2009 12:00:00 +0100 3073114 http://www.medworm.com/index.php?rid=3073115&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F484.aspx Capsule Summary - In patients with adverse prognostic indicators, the 5-year OS rate is significantly higher with amsacrine, Ara-C, etoposide followed by mitoxantrone and Ara-C. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073115 Wed, 09 Dec 2009 10:58:44 +0100 3073115 http://www.medworm.com/index.php?rid=3073116&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F116.aspx Capsule Summary - In this single-arm phase II pilot study, 75% of patients with transfusion-dependent anemia became transfusion independent following alemtuzumab therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3073116 Wed, 09 Dec 2009 09:13:08 +0100 3073116 http://www.medworm.com/index.php?rid=3068761&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F323.aspx Capsule Summary - In this nonrandomized phase II study, dose-intensified chemotherapy was associated with improved outcomes in adult ALL patients. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3068761 Tue, 08 Dec 2009 14:58:03 +0100 3068761 http://www.medworm.com/index.php?rid=3064731&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FMDS%2FCapsules%2F118.aspx Capsule Summary - In this phase II study of single-agent clofarabine, transaminase elevations and acute renal failure were the most common grade 3/4 adverse events. Further research is needed to define the optimal dosing schedule. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3064731 Mon, 07 Dec 2009 12:13:00 +0100 3064731 http://www.medworm.com/index.php?rid=3062194&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FALL%2520and%2520AML%2FCapsules%2F1061.aspx Capsule Summary - Sapacitabine safe and active in elderly AML patients (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3062194 Sun, 06 Dec 2009 17:34:58 +0100 3062194 http://www.medworm.com/index.php?rid=3080737&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202009%2FTracks%2FCML%2FCapsules%2FLBA-1.aspx Capsule Summary - According to the findings of the ENESTnd trial of 2 schedules of nilotinib (300 mg or 400 mg twice daily) vs imatinib 400 mg once daily, nilotinib more effective than imatinib at inducing MMR and CCyR in newly diagnosed patients with chronic-phase Ph-positive CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=3080737 Sat, 05 Dec 2009 00:00:00 +0100 3080737 http://www.medworm.com/index.php?rid=2460275&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7008.aspx Capsule Summary - Omacetaxine resulted in durable hematologic and cytogenetic responses with an acceptable safety profile in patients with T315I-positive chronic myeloid leukemia following failure of imatinib therapy. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2460275 Wed, 03 Jun 2009 11:18:54 +0100 2460275 http://www.medworm.com/index.php?rid=2449673&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7003.aspx Capsule Summary - Increasing the dose of daunorubicin prior to transplantation provides a survival advantage without increased toxicity in younger patients with de novo AML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2449673 Tue, 02 Jun 2009 17:58:35 +0100 2449673 http://www.medworm.com/index.php?rid=2449674&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7006.aspx Capsule Summary - GCS-100, a galectin-3 antagonist, shows antitumor and apoptotic activity and has acceptable toxicity in elderly patients with relapsed CLL. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2449674 Tue, 02 Jun 2009 17:02:59 +0100 2449674 http://www.medworm.com/index.php?rid=2449675&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FTracks%2FHematologic_Malignancies%2FCapsules%2F7043.aspx Capsule Summary - Single-agent ofatumumab therapy provided a clinically significant response rates and a survival benefit among responders, according to investigators. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2449675 Sun, 31 May 2009 16:41:49 +0100 2449675 http://www.medworm.com/index.php?rid=2384175&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%25202009%2FInteractive%2520Virtual%2520Presentations%2FIVP%2C-c-%2C%2520Ph%2B%2520ALL.aspx CCO Virtual Presentation - Jacob M. Rowe, MD, FACP, explores current thinking regarding treatment strategies for adults with acute lymphoblastic leukemia. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2384175 Thu, 30 Apr 2009 12:00:00 +0100 2384175 http://www.medworm.com/index.php?rid=2739258&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FTreatment%2520Updates%2FALL%25202009%2FInteractive%2520Virtual%2520Presentations%2FAdult%2520ALL%2520Slides.aspx CCO Slideset - Download a presentation by Adele K. Fielding, MB BS, PhD, FRCP, FRCPath, in which she reviews treatment strategies in 2 special patient populations affected by ALL: young adults and the elderly. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2739258 Thu, 23 Apr 2009 12:42:31 +0100 2739258 http://www.medworm.com/index.php?rid=2309661&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202007%2FConference%2520Sub%2520Programs%2FCML%2520Slideset%2FCCO%2520Slideset%2FSlideset%2520Module.aspx Learning Module - Download a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309661 Wed, 11 Mar 2009 00:00:00 +0100 2309661 http://www.medworm.com/index.php?rid=2309662&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCLL%2520and%2520CML.aspx Learning Module - Expert faculty members discuss the most important data in CLL and CML presented in San Francisco, California. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309662 Fri, 06 Mar 2009 14:28:11 +0100 2309662 http://www.medworm.com/index.php?rid=2309663&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FVirtual%2520Presentation%2520Programs%2FAcute%2520leukemias%2520and%2520MDS%2FAcute%2520Leukemias%2520and%2520Myelodysplastic%2520Syndromes.aspx CCO Expert Recap - Hagop M. Kantarjian, MD, provides an up-to-date analysis of the most clinically relevant new data on acute leukemias and myelodysplastic syndromes presented at the 2008 Annual Meeting of the American Society of Hematology. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309663 Thu, 26 Feb 2009 09:04:03 +0100 2309663 http://www.medworm.com/index.php?rid=2309665&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FVirtual%2520Presentation%2520Programs%2FAcute%2520leukemias%2520and%2520MDS%2FAL%2520and%2520MDS.aspx CCO Slideset - Download slides on the latest data on acute leukemias and myelodysplastic syndromes from the 2008 Hematology meeting. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309665 Wed, 14 Jan 2009 00:00:00 +0100 2309665 http://www.medworm.com/index.php?rid=2632168&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FClin%2520Onc%2520June%25202009%2FVirtual%2520Presentation%2520Programs%2FHematologic%2520Malignancies%2520ER%2FHematologic_Malignancies.aspx CCO Expert Recap - Edward Stadtmauer, MD, reviews the most important studies presented at the 2009 Clinical Oncology meeting in the settings of multiple myeloma, lymphomas, and leukemias. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2632168 Wed, 07 Jan 2009 00:00:00 +0100 2632168 http://www.medworm.com/index.php?rid=2309666&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F768.aspx Capsule Summary - Phase I/II study show sorafenib plus idarubicin and cytarabine effective and well tolerated as frontline therapy of younger patients with AML, and that sorafenib may have in vivo inhibitory activity toward ERK and FLT3 signaling. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309666 Sat, 13 Dec 2008 18:52:58 +0100 2309666 http://www.medworm.com/index.php?rid=2309667&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FAcute%2520Leukemias%2520and%2520MDS%2FCapsules%2F640.aspx Capsule Summary - Retrospective analysis of patients with primary MDS shows development of iron overload and RBC transfusion dependency both independent prognostic factors of OS and leukemia-free survival. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309667 Sat, 13 Dec 2008 14:40:32 +0100 2309667 http://www.medworm.com/index.php?rid=2309668&cid=s_29458_19_f&fid=29458&url=http%3A%2F%2Fwww.clinicaloptions.com%2FOncology%2FConference%2520Coverage%2FHematology%25202008%2FTracks%2FCLL%2520and%2520CML%2FCapsules%2F446.aspx Capsule Summary - Nilotinib induces rapid complete cytogenetic responses and has favorable toxicity profile in early chronic-phase CML. (Source: Clinical Care Options Oncology - Leukemia) Clinical Care Options Oncology - Leukemia journals http://www.medworm.com/rss/comments.php?id=2309668 Sat, 13 Dec 2008 13:22:02 +0100 2309668